Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00352261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2006
Completion date
April 30, 2007
Enrollment
80
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

barrett's esophagus